Suven Life Sciences to Present Five Scientific Posters at AAIC 2026, Highlighting Phase-3 Masupirdine and Phase-2 Usmarapride Programs 10/07/2026 / General Announcements / Clinical Development Update Suven Life Sciences to Present Five Scientific Posters at AAIC 2026, Highlighting Phase-3 Masupirdine and Phase-2 Usmarapride Programs Read Post »
Suven Life Sciences Reports Positive Phase-2b Results for Ropanicant in Major Depressive Disorder 17/06/2026 / Business Updates / Clinical Development Update Suven Life Sciences Reports Positive Phase-2b Results for Ropanicant in Major Depressive Disorder Read Post »
Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Global Phase 3 Masupirdine Study in Alzheimer’s Disease Agitation; Trial Continues Unchanged 04/06/2026 / Operations & Projects / Clinical Development Update Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Global Phase 3 Masupirdine Study in Alzheimer’s Disease Agitation; Trial Continues Unchanged Read Post »
